Many cytokine inhibitors, including those targeting IL‐1β, IL‐6, and TNF‐α, have been approved for the treatment of inflammatory diseases, such as bone destruction and rheumatoid arthritis (Rao et al., 2013). The gene discussed is IL1B; the disease is rheumatoid arthritis.